SCHEMBL30710127

SCHEMBL30710127

COc1ccc(CN(Cc2ccc(OC)cc2)c2cnc(C(F)(F)F)c(Br)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ QPCT Q16769 5/20 0.42
▸ LMNA P02545 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CHRM2 P08172 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ HTR1A P08908 1/20 0.40
▸ ADRA2A P08913 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ DRD1 P21728 1/20 0.40
▸ HTR2A P28223 1/20 0.40
▸ HTR2C P28335 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HRH1 P35367 1/20 0.40
▸ OPRM1 P35372 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26694765 1.00 QPCT (0.42) QPCTLMNAMAPTMEN1KMT2A
SCHEMBL27044000 0.82 LMNA (0.44) QPCTLMNAMAPTMEN1KMT2A
SCHEMBL26694533 0.81 LMNA (0.43) QPCTLMNAMAPTMEN1KMT2A
SCHEMBL31288424 0.81 LMNA (0.43) QPCTLMNAMAPTMEN1KMT2A
SCHEMBL30710039 0.79 QPCT (0.42) QPCTLMNAMAPTMEN1KMT2A
SCHEMBL26694781 0.79 QPCT (0.42) QPCTLMNAMAPTMEN1KMT2A
SCHEMBL30709843 0.78 UCHL1 (0.40) QPCTLMNAMAPTMEN1KMT2A
SCHEMBL30709767 0.77 CYP1A2 (0.38) QPCTLMNAMAPTMEN1KMT2A
SCHEMBL26694876 0.77 CYP1A2 (0.38) QPCTLMNAMAPTMEN1KMT2A
SCHEMBL30710088 0.76 QPCT (0.38) QPCTLMNAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4526309-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF Genentech, Inc. (US) 2025-03-26 — — EP disclosed
CN-119365467-A Aza-tetraepoxy aza compounds and uses thereof 基因泰克公司 2025-01-24 — — CN disclosed
US-20240025919-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. 2024-01-25 — — US disclosed
WO-2023225302-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2023-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025919-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF AZI2, TET3, OXA1L QPCT 2065/4885LMNA 4245/4885MAPT 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback